Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2020.0042
• Publication Date: 2020-09-04T19:22:03Z
• Authors: Aaron T. Gerds; Jason Gotlib; Prithviraj Bose; Michael W. Deininger; Andrew Dunbar; Amro Elshoury; Tracy I. George; Ivana Gojo; Krishna Gundabolu; Elizabeth Hexner; Gabriela Hobbs; Tania Jain; Catriona Jamieson; Andrew T. Kuykendall; Brandon McMahon; Sanjay R. Mohan; Vivian Oehler; Stephen Oh; Animesh Pardanani; Nikolai Podoltsev; Erik Ranheim; Lindsay Rein; Rachel Salit; David S. Snyder; Brady L. Stein; Moshe Talpaz; Swapna Thota; Pankit Vachhani; Martha Wadleigh; Katherine Walsh; Dawn C. Ward; Mary Anne Bergman; Hema Sundar
• Keywords: PDGFRB; PDGFRA; Gene rearrangement

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, may involve eosinophil-induced organ damage. In WHO classification myeloid lymphoid neoplasms, eosinophilic dysregulated tyrosine kinase (TK) fusion genes are recognized as new category termed, myeloid/lymphoid neoplasms with eosinophilia rearrangement PDGFRA , PDGFRB or FGFR1 PCM1-JAK2 . addition to these aforementioned TK genes, rearrangements involving FLT3 ABL1 have also been described. These NCCN Guidelines include recommendations for diagnosis, staging, treatment any one (MLN-Eo) gene included 2017 Classification, well MLN-Eo rearrangement.